Wound repair preserves tissue integrity through four overlapping phases—hemostasis, inflammation, proliferation, and remodeling—coordinated by platelets, neutrophils, macrophages, fibroblasts, keratinocytes, endothelial cells, and stem/progenitor cells acting with growth factors, chemokines, extracellular matrix, and intracellular signaling. Disruption of these programs results in chronic non-healing wounds or fibrotic scarring. Recent work delineates microbial influences, epigenetic and transcriptomic regulation, and cellular heterogeneity resolved by single-cell and spatial omics. Concurrent advances in biomaterials, engineered scaffolds, stem cell-derived products, and genome-targeted approaches are enabling mechanism-based therapies. Persistent challenges include wound heterogeneity, systemic modifiers such as diabetes and aging, and safe, effective delivery of biologics. This review summarizes cellular and molecular mechanisms of cutaneous repair, outlines deviations that underlie pathological healing, and evaluates emerging concepts and translational strategies. Integrating classical models with contemporary insights supports the development of precision wound medicine and personalized interventions to improve outcomes and quality of life.

Decellularized extracellular matrix (dECM) scaffolds preserve native tissue structure and biochemical cues while minimizing immune responses, creating biomimetic templates that promote cell integration and tissue remodeling. This review examines the current state of dECM research, encompassing decellularization methods, scaffold quality evaluation assays, and tissue-specific applications across dermis, nerve, heart, lung, adipose, and placental ECMs. We analyze commercially available dECM products and ongoing clinical trials, while highlighting recent advances including 3D bioprinting and the integration of dECM with stem cells and growth factors. Despite these promising developments, several challenges continue to limit broader clinical translation: protocol standardization, residual immunogenicity, mechanical durability, and regulatory, manufacturing, and cost barriers. To address these limitations, we outline future directions focusing on patient-specific scaffolds, scalable bioprocessing, and integrated biofabrication strategies that will enable the development of safe and effective dECM-based therapies.

Background: Hair health critically influences both aesthetic appearance and psychological well-being. Existing treatments often show limited efficacy and may cause side effects. Gynostemma pentaphyllum (GP), known for its antioxidant and anti-inflammatory properties, has emerged as a promising botanical agent, although clinical evidence regarding its hair health benefits remains limited. Purpose: This study aimed to evaluate the efficacy and safety of GP extract in improving hair parameters through a randomized controlled trial. Methods: This randomized, double-blind, placebo-controlled trial involved 100 eligible adults aged 19–60 years who were randomly allocated to either the GP or placebo group. Participants consumed 340 mL/day of the test product for 24 weeks. The primary outcomes included hair elasticity, density, diameter, glossiness, and subjective satisfaction. Safety was evaluated through laboratory tests and adverse event monitoring. Results: After 24 weeks, the GP group showed a threefold increase in hair elasticity and density and a fourfold increase in hair diameter compared to the placebo group. The subjective satisfaction scores corroborated these findings: the GP users reported better outcomes in terms of reducing hair damage and dryness. No significant differences in hair glossiness were observed based on the instrumental and visual assessments (p > 0.05). The safety evaluations revealed no severe adverse events. All the safety evaluation metrics demonstrated no significant abnormalities. Conclusions: This study provides compelling evidence of the efficacy of GP extract in enhancing hair health, demonstrating both significant functional improvements and an excellent safety profile. These findings substantiate its potential as a promising functional food ingredient for comprehensive hair care interventions.

The PlazMagik device is a dual-gas cold atmospheric plasma (CAP) system that was developed and used for skin rejuvenation and inflammation treatment. However, preclinical evaluation and optimization of plasma parameters are crucial for guaranteeing safety. Therefore, this study was performed to evaluate the safety of the PlazMagik device under multiple parameters with different gas resources (helium (He) and argon (Ar) gases) on pig dorsal skin. After application of PlazMagik to the pig’s dorsal skin, temperature and visual assessments were observed immediately and for up to 30 days. All clinical parameters, including body weight and blood serum biochemistry, along with histopathological analysis (H&E, MT, VB, NBTC staining), were monitored pre-application and at 1, 7, 15, and 30 days post-application of the plasma device. Our results confirmed the safety of the machine at low-output energy settings, which showed gentle skin exfoliation but no tissue damage, while high-output settings led to the skin erosion effect, then developing erythema and coagulation. Ar gas resulted in more significant heat production and pathological changes than He under identical conditions. These findings emphasize the importance of the preclinical evaluation of the energy settings and gas selection on optimizing CAP system performance for safe clinical applications and appropriate application purposes.

Wound healing remains a significant clinical challenge worldwide, and effective management strategies are essential for improving outcomes. This study evaluated SCderm Matrix, a novel acellular dermal matrix (ADM) patch developed using supercritical carbon dioxide (sCO₂) processing of human skin tissue. This innovative processing method preserves structural integrity while enhancing biocompatibility, resulting in a patch characterized by porous architecture, uniform thickness, excellent tensile strength, and optical transparency. In vivo wound healing experiments using full-thickness skin wounds in Sprague–Dawley rats demonstrated the patch’s superior performance. Treatment with the sCO₂ ADM patch accelerated wound closure, reduced inflammation, and enhanced granulation tissue formation compared to both untreated controls and two commercially available ADM products. Histological analysis revealed improved re-epithelialization and collagen deposition, while molecular and immunohistochemical assessments showed decreased reactive oxygen species (ROS) and pro-inflammatory cytokines. Simultaneously, the treatment upregulated key proliferation and remodeling markers including alpha smooth muscle actin (α-SMA), vimentin, and transforming growth factor beta 1 (TGF-β1). These findings demonstrate that the SCderm Matrix promotes wound healing through multiple mechanisms: modulating inflammatory responses, enhancing antioxidant defenses, and supporting tissue regeneration. The results suggest this biomaterial has significant potential as an effective and versatile solution for clinical wound care applications.

Objective: This study was to evaluate the effects of a composite extract of Prunus mume flower, Lonicera japonica flower (honeysuckle), Chrysanthemum indicum flower, and Phyllostachys bambusoides , which we named PLCP, on skin hydration, inflammation, itching, and oxidative stress in pediatric (NHEK) and adult (HaCaT) keratinocytes. Methods: LPS was used to simulate the external stimulation for pediatric (NHEK) and adult (HaCaT) keratinocytes. These keratinocytes were treated with different concentrations of PLCP, and the expression of inflammation, itching, and oxidative stress‐related proteins or mRNA was observed through rt‐PCR, ELISA, ROS, and SOD. Meanwhile, rt‐PCR was also used to determine the expression of Hyaluronic acid synthase (HAS) in keratinocytes under PLCP intervention for its moisturizing effects. Results: PLCP treatment (0.125%–0.500%) significantly suppressed LPS‐stimulated thymic stromal lymphopoietin (TSLP) secretion by up to 40.3% in pediatric cells and 29.9% in adult cells ( p < 0.05), and reduced endothelin‐1 (ET‐1) mRNA levels by up to 69.5% and 46.0%, respectively ( p < 0.05). Concurrently, PLCP dose‐dependently upregulated hyaluronic acid synthase isoforms (HAS‐1, HAS‐2, HAS‐3) mRNA expression by 174.8%–254.2% in pediatric keratinocytes and 143.5%–198.9% in adult cells ( p < 0.05), indicating enhanced hydration potential. Antioxidant assays demonstrated that PLCP at 0.250% decreased reactive oxygen species (ROS) by 55.3% in pediatric and 41.6% in adult cells, while boosting superoxide dismutase (SOD) activity ( p < 0.05). Conclusions: Across all endpoints, pediatric keratinocytes exhibited more pronounced responses, suggesting age‐dependent differences in sensitivity. These in vitro findings support PLCP's multifunctional role at anti‐inflammatory, anti‐pruritic, moisturizing, and antioxidant and highlight its promise as a safe, plant‐based alternative for managing pediatric skin disorders.